Fate Therapeutics (FATE) names Matthew Abernethy to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| FATE THERAPEUTICS (NASDAQ: FATE) | Delayed: 2.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.11 | 52 Week High | $4.76 | |||
| Open | $2.11 | 52 Week Low | $1.46 | |||
| Day High | $2.11 | P/E | N/A | |||
| Day Low | $2.11 | EPS | $-1.91 | |||
| Volume | 588 | |||||
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 142.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.70 | 52 Week High | $58.46 | |||
| Open | $142.70 | 52 Week Low | $31.25 | |||
| Day High | $142.70 | P/E | N/A | |||
| Day Low | $142.70 | EPS | $-0.69 | |||
| Volume | 5 | |||||
